FDA's Califf on congressional report on Aduhelm controversy; Illumina gives Wall Street bad news

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: FDA scolds Sun Pharmaceutical for serious quality control problems at a key plant in India By Ed Silverman Sarah Silbiger/Getty Images This marks at least the third time in recent years that the FDA cited the same Sun Pharmaceutical facility for manufacturing problems. Read More STAT+: An FDA pathway to clear medical devices is putting patients at risk, research suggests By Matthew Herper Adobe New research examines medical devices cleared through the FDA's 510(k) pathway based on existing devices that have had a recall. Read More STAT+: FDA's Califf says congressional report on Aduhelm controversy contained 'no surprises' By Jonathan Wosen STAT FDA head Robert Califf made his first public comments following a congressional investigation into the agency’s role in approving Aduhelm. Read More Sponsored Insight by STAT+ You're invited to STAT's JPM Recap On Jan. 13, get a full rundown of the deals, data, and scuttlebutt from the STAT reporters who attended the conference, and come away with insights you won't get anywhere else. Sign up here. STAT+: Illumina, the DNA sequencing giant, gives Wall Street bad news By Matthew Herper Adobe Illumina said its consolidated earnings per share would be in the range of $1.25, dramatically below the expected $2.99 per share. Read More STAT+: Hospitals say peak labor costs are behind them By Bob Herman Bob Herman/STAT Rising labor costs have been the main financial concern for hospitals over the past year, but those costs have peaked and gone way down. Read More Tuesday, January 10, 2023       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser